title: New drug interactions with zidovudine.
abstract: Polypharmacy is commonly encountered in human immunodeficiency virus (HIV)-positive patients, and the risk and frequency of drug-drug interactions are significant in this patient population. Most HIV-positive patients receive the antiretroviral drug zidovudine (3'-azido-3'-deoxythymidine, ZDV), the first drug to be approved for the treatment of HIV. Many drug interactions with ZDV have already been reported. As HIV pharmacotherapy becomes more complex, the potential for drug-drug interactions is likely to increase significantly.
authors.affiliation: Faculty of Pharmacy, University of Toronto, Ontario, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Robertson-Dallas
authors.forename: S E
authors.initials: SE
authors.lastname: Read
authors.forename: R
authors.initials: R
authors.lastname: Bendayan
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D010599:Pharmacokinetics; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine